EN DE
Watch Mediantechn for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mediantechn (ALMDT) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Mediantechn stock €3.26, price €3.90, that is 16.4% below the price, quality 23 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0011049824

M Mediantechn logo Thin data Nov 10, 2026

Mediantechn

ALMDT · PA
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Expensive Growth (revenue 5y +11.6 %/yr in EUR)
Negative equity (buybacks among others)
Fair value €3.26 · Overvalued
Quality 23/100
Loss-making · -145.2% net margin (TTM)
Negative free cash flow
Trails peers (0/7)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Mediantechn for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€17.80 €1.20 Fair Value €3.26 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range €1.20 – €17.80 · fair‑value band €2.44 – €4.07 · the €3.90 price screens above the €3.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Mediantechn in your weekly email

Every Wednesday you see whether Mediantechn is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally.

Show moreShow less

The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnostic tests based on imaging for the diagnosis and treatment of patients suffering from cancer; and iCRO, a central imaging service and AI-powered Imaging Lab. Also, the company focuses on the oncology clinical trials market and the cancer patient care market.

The company was founded in 2002 and is based in Valbonne, France.

Stock analysis

Mediantechn (ALMDT) currently trades at €3.90, while our estimate is €3.26, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €2.44 (bear) to €4.07 (bull), the price of €3.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Mediantechn reported revenue of €23.4M in FY2025 versus €20.5M in FY2021, a compound +3.3%/yr. Reported net income was −€34.1M in FY2025.

Key figures

Market cap €190M Micro · P/S ratio 7.70 · EPS (TTM) €−0.9300 · Net margin −145% · Return on equity −511% · Return on assets (EBIT) −57.1% (5-year average) · Operating margin −57.8% · Revenue (TTM) €23.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −16%, ALMDT screens richer than that median.

Fair Value

Bear €2.44 Fair Value €3.26 Bull €4.07
Price €3.90 · Downside -16.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 65
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 47
Does it invest with discipline instead of growing at any price?
Low Volatility 47
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 45
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic). Over 10 years: +19.6% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−65.4% (2020) → −58.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALMDT screens overvalued: fair value 16% below the price. Compare with Abbott Laboratories, →

Compare Mediantechn with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −16.4% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −95.0% · Bottom 25%
Net margin (12 months) −145.2% · Bottom 25%
Operating margin (12 months) −57.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.7% · Below median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 8.09× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 17
FUTURE (revenue growth)4 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs ALMDT
DexCom, Inc DXCM $79.92 $89.18 +12% vs ALMDT
Stryker Corporation SYK $324.29 $358.30 +10% vs ALMDT
STERIS plc STE $257.12 $279.53 +9% vs ALMDT
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs ALMDT
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs ALMDT
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs ALMDT
Abbott Laboratories, ABT $110.46 $75.28 −32% vs ALMDT
Medtronic plc MDT $101.59 $65.61 −35% vs ALMDT
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs ALMDT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mediantechn: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mediantechn Fair Value". https://www.fairvalue-calculator.com/stock/ALMDT

Frequently asked questions

Is Mediantechn (ALMDT) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €3.26 versus a price of €3.90, about 16% lower (overvalued).
What is the fair value of ALMDT?
Our estimate for Mediantechn is €3.26 (as of Nov 10, 2026), built from audited fundamentals. The current price: €3.90.
What is the quality score of ALMDT?
Mediantechn has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mediantechn (ALMDT)?
Our calculated price target is the estimate of €3.26 (as of Nov 10, 2026). Cautious scenario €2.44, optimistic scenario €4.07. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Mediantechn stock forecast for 2026?
Our estimate puts fair value at €3.26, about 16% lower versus a price of €3.90 (overvalued). Cautious scenario €2.44, optimistic scenario €4.07. The calculation is refreshed regularly with new filings.
What is the revenue of Mediantechn (ALMDT)?
Mediantechn reported trailing-twelve-month revenue of about €23.5M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Mediantechn (ALMDT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mediantechn it is €3.26 per share (as of Nov 10, 2026), against a price of €3.90.
Is Mediantechn stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ALMDT trades above its calculated fair value: price €3.90, fair value €3.26, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALMDT?
No. The price is what the market pays today (€3.90); the fair value is what the company's own numbers justify (€3.26). For Mediantechn the two are €0.6400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mediantechn worth?
The market values Mediantechn at about €190M (market capitalisation, as of Nov 10, 2026). Per share that is €3.90; our models calculate a fair value of €3.26 per share.
What do the bullish and bearish scenarios say about ALMDT?
Our models span a range for Mediantechn: cautious scenario €2.44, base €3.26, optimistic €4.07 per share (as of Nov 10, 2026, price €3.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mediantechn (ALMDT)?
Balance-sheet figures for Mediantechn (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is ALMDT from its 52-week high?
Mediantechn trades at €3.90, about 41% below its 52-week high of €6.59 and 42% above the low of €2.76 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €3.26 is for.
Which stocks are comparable to Mediantechn?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mediantechn stock attractive at the current price?
The data as of Nov 10, 2026: price €3.90, calculated fair value €3.26 (−16%), Quality Score 23/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Mediantechn itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mediantechn (ALMDT)?
The closing price on Nov 10, 2026 was €3.90. Our estimate is €3.26, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mediantechn right now?
Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Mediantechn

How large is the market capitalisation of Mediantechn (ALMDT)?
The market capitalisation of Mediantechn is €190M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mediantechn (ALMDT)?
The price-to-sales ratio of Mediantechn is 7.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mediantechn (ALMDT)?
Earnings per share at Mediantechn are €−0.9300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Mediantechn (ALMDT)?
The net margin of Mediantechn is −145% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mediantechn (ALMDT)?
The return on equity (ROE) of Mediantechn is −511% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mediantechn (ALMDT)?
On an EBIT basis the return on assets of Mediantechn is −57.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mediantechn (ALMDT)?
The operating margin of Mediantechn is −57.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mediantechn (ALMDT)?
Revenue at Mediantechn is growing +0.7% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Mediantechn (ALMDT) generate?
The free cash flow of Mediantechn is −€18.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mediantechn (ALMDT) carry?
The net debt of Mediantechn is €3.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Mediantechn in the live analysis

One click puts Mediantechn on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.